Released: 9-Sep-2011 9:00 AM EDT
Researchers Use New Tool To Counter Multiple Myeloma Drug Resistance
Moffitt Cancer Center

Moffitt Cancer Center researchers, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of acquired drug resistance and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

Released: 15-Sep-2011 11:30 AM EDT
Researchers Find Possible Key To Preventing Chemotherapy Resistance In Ovarian Cancer
Moffitt Cancer Center

Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance. They are hopeful that the discovery may lead to therapies that are tailored to individual patients with ovarian cancer.

Released: 21-Sep-2011 11:25 AM EDT
Scientists Identify A Key Molecule That Blocks Abnormal Blood Vessel Growth In Tumors
Moffitt Cancer Center

A new and better understanding of blood vessel growth and vascular development (angiogenesis) in cancer has been made possible by research by a team of scientists from Moffitt Cancer Center, the University of Florida, Harvard University, Yale University and the Children’s Hospital of Los Angeles.

Released: 29-Sep-2011 11:45 AM EDT
Impediment To Some Cancer Immunotherapy Involves Free Radical Peroxynitrite
Moffitt Cancer Center

Researchers have found that tumor cell resistance to a specific cancer immunotherapy designed to kill cancer cells can be blamed on a mechanism that involves the production of a free radical peroxynitrite (PNT) that causes resistance to therapeutic cancer-killing cells.

Released: 6-Oct-2011 12:10 PM EDT
Earlier Circumcision In Males May Be Effective Intervention To Slow Rates Of HIV And HPV Transmission In South Africa
Moffitt Cancer Center

According to a researcher at Moffitt Cancer Center in Tampa, Fla., and her colleagues in the Netherlands, earlier circumcision of males in South Africa may be a positive step in slowing the spread of both HIV and the human papillomavirus (HPV). Their commentary and data were published in a recent issue of the British medical journal The Lancet Infectious Diseases.

Released: 21-Oct-2011 12:00 PM EDT
Researchers Get $3M NIH Grant To Develop Mathematical Models Of Prostate Cancer Aggressiveness
Moffitt Cancer Center

Alexander R. A. Anderson, Ph.D., co-director of Integrative Mathematical Oncology at Moffitt Cancer Center, and colleagues, Simon Hayward, Ph.D., at Vanderbilt University and Gustavo Ayala, M.D., at Baylor College of Medicine, have received a five-year, $3 million grant from the National Institutes of Health to create new mathematical models to predict prostate cancer aggressiveness.

Released: 27-Oct-2011 11:15 AM EDT
Researchers Find More Clues To Causes Of Breast Cancer
Moffitt Cancer Center

Publishing in the current issue of The Journal of Biological Chemistry, Moffitt Cancer Center researchers have discovered additional mechanisms of “Akt” activation and suggest a component of that activation mechanism – inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) – could be targeted as a therapeutic intervention for treating cancer.

Released: 28-Oct-2011 10:15 AM EDT
Cancer Survivorship Research Must Look At Quality Of Life
Moffitt Cancer Center

Assessing the quality of life experienced by cancer survivors is becoming increasingly important, say Moffitt Cancer Center researchers. Such an assessment has a number of important applications when doing research on cancer survivorship, but just how to measure quality of life for cancer survivors is still being developed.

Released: 28-Oct-2011 11:45 AM EDT
Consortium Gets $7.2 M Contract Renewal To Promote Phase II Clinical Trials
Moffitt Cancer Center

The National Cancer Institute recently awarded $7.2 million for the competitive renewal of the Southeast Phase 2 Consortium (SEP2C), led by Moffitt Cancer Center’s Daniel Sullivan, M.D., executive vice president and associate center director for Clinical Investigations.

Released: 31-Oct-2011 11:40 AM EDT
Researchers Find Regulatory T-Cell Clue To Help Prevent GVHD
Moffitt Cancer Center

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, Moffitt Cancer Center researchers have tested a process by which T regulatory cells (Tregs) can be “expanded” to help prevent GVHD.

Released: 3-Nov-2011 10:45 AM EDT
Researchers Help In Search For New Ways To Image, Therapeutically Target Melanoma
Moffitt Cancer Center

Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center and colleagues at Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy. A tool of great promise comes from the world of nanomedicine – where tiny drug delivery systems are measured in the billionths of meters and are being designed to deliver targeted therapies.

Released: 9-Nov-2011 11:00 AM EST
Researchers Unravel Biochemical Factor Important In Tumor Metastasis
Moffitt Cancer Center

A protein called “fascin” appears to play a critical transformation role in TGF beta mediated tumor metastasis, say researchers at Moffitt Cancer Center, who published a study in a recent issue of the Journal of Biological Chemistry.

Released: 22-Nov-2011 11:45 AM EST
Researchers Find Men Less Willing To Be Screened For Cancer
Moffitt Cancer Center

Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry.

Released: 2-Dec-2011 10:45 AM EST
Researchers Find MK1775 Active Against Sarcomas
Moffitt Cancer Center

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas – especially sarcomas affecting children – may be at hand.

Released: 5-Dec-2011 7:00 AM EST
Florida Cancer Researchers Will Be Strong Participants In American Society Of Hematology Meeting
Moffitt Cancer Center

When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

Released: 5-Dec-2011 12:30 PM EST
Follow-Up Study Finds Prolonged Fatigue For Those Who Received Chemotherapy For Breast Cancer
Moffitt Cancer Center

In a follow-up study, researchers at Moffitt Cancer Center and colleagues have found that patients who receive chemotherapy for breast cancer might experience prolonged fatigue years after their therapy. The new study, published in the American Cancer Society’s current issue of CANCER, is a follow-up to a study on fatigue and chemotherapy and radiotherapy for breast cancer Moffitt researchers published in CANCER in 2007.

Released: 8-Dec-2011 4:15 PM EST
Researchers Find Smoking Is Strongly Associated With Squamous Cell Carcinoma Among Women
Moffitt Cancer Center

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center, who published study results in a recent issue of Cancer Causes Control.

Released: 13-Dec-2011 3:15 PM EST
Researchers Find Potential Target For Treating Metastatic Cancer
Moffitt Cancer Center

Finding ways to counteract or disrupt the invasive nature of cancer cells, called “metastasis,” has been a long-term goal of cancer researchers. Now, Moffitt Cancer Center researchers have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.

Released: 5-Jan-2012 9:55 AM EST
Fibroblasts Contribute To Melanoma Tumor Growth
Moffitt Cancer Center

Fibroblasts, cells that play a role in the structural framework of tissues, play an apparent role in melanoma tumor growth. Fibroblasts also contribute to melanoma drug resistance and may also facilitate the “flare” response when a tumor’s metabolism is enhanced following a patient being removed from a targeted therapy, said researchers at Moffitt Cancer Center.

Released: 6-Jan-2012 11:30 AM EST
Researchers Find Malignancy-Risk Gene Signature For Early-Stage Non-Small Cell Lung Cancer
Moffitt Cancer Center

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center, who published their study results in a recent issue of the Journal of the National Cancer Institute.

Released: 12-Jan-2012 11:00 AM EST
Researchers Find New, Noninvasive Way To Identify Lymph Node Metastasis
Moffitt Cancer Center

Using two cell surface markers found to be highly expressed in breast cancer lymph node metastases, researchers at Moffitt Cancer Center, working with colleagues at other institutions, have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases. The new procedure could spare breast cancer patients invasive and unreliable sentinel lymph node (SLN) biopsies and surgery-associated negative side effects.

Released: 19-Jan-2012 10:00 AM EST
Study Finds Potential Key To Immune Suppression In Cancer
Moffitt Cancer Center

In a study investigating immune response in cancer, Moffitt Cancer Center and University of South Florida researchers have found that interaction between the immune system’s antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) – cells that play a major role in cancer-related immune suppression – dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system’s CD8 T cells.

Released: 30-Jan-2012 12:30 PM EST
Cancer Patients’ Pain Can Be Helped By Psychosocial Interventions
Moffitt Cancer Center

Researchers at Moffitt Cancer Center, who teamed with colleagues at five universities around the United States, analyzed past studies of cancer-related pain reduction and found that psychosocial interventions can have a beneficial effect on cancer patients’ pain severity.

Released: 7-Feb-2012 12:30 PM EST
Researchers Find Ovarian Cancer Risk Related To Inherited Inflammation Genes
Moffitt Cancer Center

In a study conducted by researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the Unites States and the United Kingdom, genes that are known to be involved in inflammation were found to be related to risk of ovarian cancer.

Released: 8-Feb-2012 11:05 AM EST
Partnership Focuses On Cancer Education And Outreach In Puerto Rico
Moffitt Cancer Center

A description of the projects and studies resulting from a research partnership initiated in 2005 between Moffitt Cancer Center in Florida and the Ponce School of Medicine in Ponce, Puerto Rico, has been published in a recent issue of Health Promotion Practice. The partnership included three outreach cancer education projects and two pilot research studies aimed at reducing cancer health disparities in Hispanic populations in both Tampa and Ponce.

Released: 9-Feb-2012 12:15 PM EST
Researchers Find Important ‘Target’ Playing Role in Tobacco-Related Lung Cancers
Moffitt Cancer Center

Researchers at Moffitt Cancer Center have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce IKBKE and, in turn, IKBKE induces chemotherapy resistance.

Released: 14-Feb-2012 10:25 AM EST
New Patent Promises to Accelerate Cancer Trials
Moffitt Cancer Center

A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient’s own molecular profile – warehoused in a database of thousands of patient-donated biological tissue or tumor samples – to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly.

Released: 15-Feb-2012 11:15 AM EST
Female Cancer Survivors Have 'Worse Health Behaviors' Than Women With No Cancer History
Moffitt Cancer Center

A recent study conducted by researchers at Moffitt Cancer Center and the Mayo Clinic has found that female cancer survivors receiving screening mammography have “worse health behaviors” than women receiving mammography screening and who had never had cancer.

Released: 22-Feb-2012 11:15 AM EST
Researchers Evaluate Teaching Program For Breaking Bad News To Patients
Moffitt Cancer Center

Researchers at Moffitt Cancer Center and the University of South Florida College of Medicine evaluated the experience of medical students who participated in videotaped sessions where they practiced conveying difficult news to “standardized patients” (SPs). The SPs role-played patients with a variety of cancers and who were receiving bad medical news.

Released: 28-Feb-2012 3:45 PM EST
Researchers Find Potential Solution To Melanoma’s Resistance To Vemurafenib
Moffitt Cancer Center

Researchers at Moffitt Cancer Center and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

Released: 1-Mar-2012 11:20 AM EST
Researchers Find Sarcoma Tumor Immune Response With Combination Therapy
Moffitt Cancer Center

A team of 18 researchers at Moffitt Cancer Center have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external beam radiation (EBRT) provided more than 50 percent of their trial patients with tumor-specific immune responses lasting from 11 to 42 weeks.

Released: 6-Mar-2012 10:25 AM EST
Researchers Find Possible Genetic Keys To Surviving Epithelial Ovarian Cancer
Moffitt Cancer Center

Researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the United States and the United Kingdom have used two genome-wide association studies (GWAS) – one from the U.S. and one from the U.K. – to detect a novel set of genes found to be associated with epithelial ovarian cancer patient survival. The discovery could open the door to new therapies for treating epithelial ovarian cancer (EOC), the most lethal kind of gynecologic malignancy.

Released: 12-Mar-2012 10:00 AM EDT
Researchers Participate in Society for Research on Nicotine and Tobacco's Annual Meeting
Moffitt Cancer Center

Researchers from Moffitt Cancer Center are participating in the 18th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT) from March 13-16 at the Hilton Americas Houston Hotel in Texas.

Released: 16-Mar-2012 11:45 AM EDT
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
Moffitt Cancer Center

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.

Released: 19-Mar-2012 11:45 AM EDT
Researchers Find That Smoking May Restore Tapped-Out Self-Control Resources
Moffitt Cancer Center

Researchers at Moffitt Cancer Center in Tampa, Fla., have found that when they deplete a smoker’s self control, smoking a cigarette may restore self-control.

   
Released: 23-Mar-2012 11:00 AM EDT
Identifying Acute Myeloid Leukemia Gene Mutations May Indicate Risk, Best Treatment
Moffitt Cancer Center

An international group of researchers, including those from Moffitt Cancer Center, have published a paper in the March 14 issue of the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia (AML). They found that several mutated genes predicted improved outcomes when patients with certain gene mutations were given high-dose induction chemotherapy.

Released: 23-Mar-2012 4:00 PM EDT
Researchers Link Stigma to Depression Among Lung Cancer Patients
Moffitt Cancer Center

Studying the role of social stigma in depression for lung cancer patients, researchers at Moffitt Cancer Center in Tampa, Fla., have found that depression can be heightened by a lung cancer patient’s sense of social rejection, internalized shame and social isolation. These factors may contribute to depression at rates higher than experienced by patients with other kinds of cancer.

Released: 28-Mar-2012 10:15 AM EDT
Does Body Mass Index Affect Post-Surgical Complications, Survival In Esophageal Adenocarcinoma?
Moffitt Cancer Center

Researchers at Moffitt Cancer Center have found – contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) – that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.

Released: 28-Mar-2012 3:30 PM EDT
Myeloid Malignancies Underreported In U.S.
Moffitt Cancer Center

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001.

Released: 3-Apr-2012 9:00 AM EDT
Researchers Validate New Staging Classifications for Neuroendocrine Pancreatic Tumor Surgery Response
Moffitt Cancer Center

Researchers at Moffitt Cancer Center have carried out a study to validate the utility of new tumor classification systems for staging and predicting relapse-free survival for patients with neuroendocrine tumors (NETs) and who may be candidates for surgery.

Released: 19-Apr-2012 3:30 PM EDT
Many Breast Cancer Survivors Worry About Cancer Returning
Moffitt Cancer Center

“Cancer worry” is the fear that cancer will return, said researchers at Moffitt Cancer Center who studied cancer worry among breast cancer survivors and published their findings in Psycho-Oncology. They found that even three years after successful treatment, two-thirds of the 202 breast cancer survivors who participated in their study said they had “a moderate level of worry.”

Released: 20-Apr-2012 10:00 AM EDT
Cancer Therapies Affect Cognitive Functioning Among Breast Cancer Survivors
Moffitt Cancer Center

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer.

Released: 27-Apr-2012 1:00 PM EDT
Moffitt Cancer Center Begins 26th Year with Emphasis on Research, Patient Care
Moffitt Cancer Center

After celebrating its 25th anniversary in 2011, Moffitt Cancer Center is continuing its mission “to contribute to the prevention and cure of cancer.” “As one of 41 National Cancer Institute-designated Comprehensive Cancer Centers nationwide, we are continuing to lead in scientific discovery and cancer research and also in translating research and discovery into state-of-the-art patient care,” said William S. Dalton, Ph.D., M.D., president and CEO of Moffitt.

Released: 27-Apr-2012 1:00 PM EDT
Moffitt Cancer Center Researcher Awarded GE Grant to Develop Tool to Detect Breast Cancer Metastasis Genetic Risks
Moffitt Cancer Center

M. Catherine Lee, M.D., breast cancer researcher and assistant member at Moffitt Cancer Center, has received a $100,000 grant from General Electric’s $100 million healthymagination Challenge to develop genetic tools to investigate an individual’s genetic makeup to determine if they are predisposed to develop or resist breast cancer metastasis.

Released: 27-Apr-2012 1:00 PM EDT
Moffitt Cancer Center Researcher Publishes Book on Nutritional Management of Cancer Treatment Effects
Moffitt Cancer Center

Nagi B. Kumar, Ph.D., R.D., F.A.D.A., a senior member and director of Cancer Chemoprevention at Moffitt Cancer Center, is the author of a landmark book Nutritional Management of Cancer Treatment Effects, published by Springer International (2012).

Released: 27-Apr-2012 1:00 PM EDT
Quality of Life as Important as Quantity of Life
Moffitt Cancer Center

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

Released: 27-Apr-2012 1:00 PM EDT
Moffitt Cancer Center Researchers Working at Frontiers of Melanoma Research
Moffitt Cancer Center

At Moffitt Cancer Center, patients with stage III and IV unresectable melanoma are now routinely genetically profiled for several gene mutations, including the BRAF gene, a known driver oncogene for melanoma. Research has shown that mutations in the BRAF gene determine sensitivity or resistance to a class of drugs that are BRAF inhibitors.

Released: 27-Apr-2012 1:00 PM EDT
Researchers Are Creating “Designer Lymph Nodes” Based on Moffitt Cancer Center’s Total Cancer Care™ Initiative
Moffitt Cancer Center

Researchers at Moffitt Cancer Center are in the first phase of creating “designer lymph nodes.” Designer lymph nodes are built with specialized gene-modified cells that are injected into patients and produce a pre-planned immunologic response for cancer patients locally and then throughout their bodies. The researchers are examining a cancer vaccine “boosting” effect of the manufactured lymph nodes in patients with advanced melanoma.

Released: 27-Apr-2012 1:00 PM EDT
Moffitt Cancer Center Researcher of the Year Sharpens Focus on Infection and Its Links to Cancer in Men and Women
Moffitt Cancer Center

Anna R. Giuliano, Ph.D., director of the newly created Center for Infection Research in Cancer at Moffitt Cancer Center, is world renowned for her research on the human papillomavirus (HPV) and the variety of cancers linked to it that affect both men and women. She was recently appointed to lead this new center to expand Moffitt’s efforts to find other links between infections and cancer.

Released: 27-Apr-2012 1:00 PM EDT
Adolescents with Cancer Concerned about Their Future Reproductive Health
Moffitt Cancer Center

Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child’s reproductive concerns.


close
1.01912